evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Eyes and Vision

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Tocilizumab weekly vs placebo + 52‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 26‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review